{
    "organizations": [],
    "uuid": "79c78c50bf1aac22457c1d17c09ebb44e7bbeb56",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-allergan-announces-positive-phase/brief-allergan-announces-positive-phase-3-results-for-ubrogepant-idUSFWN1PW0MI",
    "ord_in_thread": 0,
    "title": "BRIEF-Allergan Announces Positive Phase 3 Results For Ubrogepant",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 6 (Reuters) - Allergan Plc:\n* ALLERGAN ANNOUNCES POSITIVE TOP LINE PHASE 3 RESULTS FOR UBROGEPANT - AN ORAL CGRP RECEPTOR ANTAGONIST FOR THE ACUTE TREATMENT OF MIGRAINE\n* STUDY MEETS CO-PRIMARY ENDPOINTS IN FIRST OF TWO PHASE 3 STUDIES\n* STUDY MEETS CO-PRIMARY ENDPOINTS IN FIRST OF TWO PHASE 3 STUDIES\n* RESULTS OF SECOND PHASE 3 TRIAL, ACHIEVE II (UBR-MD-02), ARE EXPECTED IN 1ST HALF OF 2018\n* ALLERGAN - ANTICIPATES FILING NDA TO FDA FOR ACUTE MIGRAINE TREATMENT DRUG IN 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-06T20:03:00.000+02:00",
    "crawled": "2018-02-07T22:21:28.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "allergan",
        "plc",
        "allergan",
        "announces",
        "positive",
        "top",
        "line",
        "phase",
        "result",
        "ubrogepant",
        "oral",
        "cgrp",
        "receptor",
        "antagonist",
        "acute",
        "treatment",
        "migraine",
        "study",
        "meet",
        "endpoint",
        "first",
        "two",
        "phase",
        "study",
        "study",
        "meet",
        "endpoint",
        "first",
        "two",
        "phase",
        "study",
        "result",
        "second",
        "phase",
        "trial",
        "achieve",
        "ii",
        "expected",
        "1st",
        "half",
        "allergan",
        "anticipates",
        "filing",
        "nda",
        "fda",
        "acute",
        "migraine",
        "treatment",
        "drug",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}